From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.

Affiliation

Medical Oncology Unit, University Hospital of Parma, Italy. Electronic address: [Email]

Abstract

Analysis of circulating tumor DNA (ctDNA) for the identification of T790M mutation in advanced EGFR-mutated NSCLC patients can replace tissue re-biopsy for resistance characterization and, being non-invasive, may be applied for disease monitoring. We analysed ctDNA during osimertinib treatment to correlate mutational levels with clinical outcome and to predict pattern of resistance.

Keywords

EGFR mutation,Liquid biopsy,NSCLC,Osimertinib,T790M,

OUR Recent Articles